You are here

Article info

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘A pilot study of tofacitinib for refractory Behçet’s syndrome’’ by Zou et al

Authors

  • Jinjing Liu Department of Rheumatology and Clinical Immunology, Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Chan Zhao Department of Ophthalmology, Peking Union Medical College Hospital, Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Wenjie Zheng Department of Rheumatology and Clinical Immunology, Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Wenjie Zheng, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing 100730, China; wenjzheng{at}gmail.com
View Full Text

Citation

Liu J, Zhao C, Zheng W
Response to: ‘Correspondence on ‘A pilot study of tofacitinib for refractory Behçet’s syndrome’’ by Zou et al
Annals of the Rheumatic Diseases 2023;82:e101.

Publication history

  • Received January 5, 2021
  • Revised January 8, 2021
  • Accepted January 8, 2021
  • First published January 25, 2021.
Online issue publication 
March 10, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.